New to Zacks? Get started here.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.
If you wish to go to ZacksTrade, click
OK. If you do not, click Cancel.
Back to top
In a bid to boost its Qualitest (formerly generics) portfolio,
Endo Health Solutions ( ENDP - Analyst Report) announced its intention to acquire privately-held generics company Boca Pharmacal for $225 million in cash. Endo Health intends to finance the deal, expected to close by year end, with its available cash balance.
While releasing its second quarter 2013 results earlier in the month, Endo Health had stated that it expects adjusted earnings per share for 2013 in the range of $4.25-$4.55. The acquisition, on closure, is expected to boost Endo Health’s 2013 adjusted earnings per share.
The news of the impending acquisition had a positive impact on Endo Health’s stock price. Buoyed by the news, Endo Health hit a 52-week high of $40.79 per share on Aug 28, 2013.
The decision to buy Boca Pharmacal, which focuses on the commercialization and development of products including controlled substances, semisolids, and solutions, is a smart move by Endo Health as it prepares to combat the decline in revenues due to genericization of its key painkillers.
Endo Health’s revenues in the second quarter of 2013 declined on a year-over-year basis due to lower sales of Opana ER. Opana ER sales were hurt by generic competition during the second quarter.
We note that another painkiller at Endo Health, Lidoderm will be facing generic competition from Actavis, Inc. shortly. In Aug 2012, the U.S. Food and Drug Administration had cleared Actavis’ generic version of Lidoderm. However, Actavis’ agreement with Endo Health prohibits the former from selling the drug prior to Sep 15, 2013.
We note that the Qualitest segment at Endo Health performed well in the second quarter of 2013 with sales climbing 7% to $170.5 million driven by increased demand for generic drugs. The acquisition of Boca Pharmacal, on completion, should boost segmental sales further.
Endo Health carries a Zacks Rank # 3 (Hold). Companies such as Gilead Sciences Inc. ( GILD - Analyst Report) and Actelion Ltd. ( ALIOF - Snapshot Report) currently appear to be well placed. Both stocks carry a Zacks Rank #1 (Strong Buy).